ipamorelin e tesamorelin + Blend — GHRH Research Tesamorelin 10mg — Only FDA-Approved

This peptide is designed to stimulate the release of growth hormone from the pituitary gland in a pulsatile manner, leading to increased levels of growth hormone in the body

Echocardiographic parameters Prior to each echocardiography recording, animals were lightly sedated as recommended (Stein et al., 2007) with an intraperitoneal administration of ketamine (50 mg/kg) + xylazine (5 mg/kg), and placed in supine position in a stable horizontal plane

Short to medium term use appears safe based on available evidence

Because Tesamorelin specifically targets abdominal fat while Ipamorelin supports lean mass maintenance, it provides a unique framework for investigating the reversal of metabolic syndrome

In certain embodiments, pharmaceutical compositions in accordance with the present disclosure may be administered at dosage levels sufficient to deliver from about 0.0001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, or from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic, diagnostic or prophylactic effect